following the money

New report shows what industries in Houston are attracting the most venture capital investment

According to a new report, Houston's energy and health care industries are attracting the most VC investment — with cleantech and oncology investments specifically on the rise. Graphic via the Houston Tech Report by the GHP

According to a recently released report, a few key industries in Houston have attracted the bulk of the city's venture capital investment dollars.

The Houston Tech Report by the Greater Houston Partnership and Houston Exponential has revealed that the city is home to 8,800 tech-related firms, including over 700 venture-backed startups that have attracted over $2.6 billion in VC funding over the past five years. Annual VC investment has tripled in that same timeframe — from $284 million in 2016 to $753 million in 2020.

"Houston is a city that has been leading the way for decades, with breakthrough innovations that have truly changed the world," says Bob Harvey, president and CEO of the Greater Houston Partnership, in a news release. "Over the past few years, we have been working to transform an already incredible economy into one that competes as a leading digital tech city."

Zooming into the industries attracting the most capital in Houston, life sciences and oil and gas technology continue to reign supreme. Of the VC dollars going into Houston companies, 17 percent goes into life science companies and 17 percent goes into oil and gas, according to the report. Cleantech and Oncology are both niches in Houston that have seen growth in VC investment.

Graphic via the Houston Tech Report by the GHP

Software as a service has seen significant growth since 2011, and represents the third-most invested in industry with 14 percent of the VC investment.

Contributing to the innovation ecosystem's growth is an increase in startup development organizations — the city now has added over 30 SDOs including non-profits, incubators/accelerators, coworking spaces and makerspaces since 2017 — and access to tech talent. According to the report, Houston has the 12th largest tech sector in the U.S. with 235,000 tech workers, and this sector generates $28.1 billion to the region's GDP.

"Houston in 2020 had not one but two unicorns (private tech companies exceeding a $1 billion valuation), our first ever," says Harvin Moore, president of HX. "That's a reflection of both the rate of growth and early stage of our ecosystem. We will see an increasing number of startups as these companies continue to grow and others follow."

Graphic via the Houston Tech Report by the GHP

According to the report, the most active investors into Houston-based companies between 2017 and 2020 include Austin-based Capital Factory with 29 deals, Houston-based TMC Innovation with 25 deals, and Houston Angel Network with 23 deals.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted